Position in NAMS
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$223,674
+$12,408 QoQ
Shares Held
6,600
0.0% QoQ
Ownership
0.006%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#159
of 198 holders
Holding Since
Dec 2025
3 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in NAMS Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Allianz Asset Management GmbH holds $690,566,615 across 64 Biotechnology names. NAMS ranks #58 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | REGN |
Regeneron Pharmaceuticals, Inc.
|
327,683 | $204,323,456 | |
| 2 | JAZZ |
Jazz Pharmaceuticals plc
|
564,696 | $136,074,794 | |
| 3 | MRNA |
Moderna, Inc.
|
989,897 | $69,322,486 | |
| 4 | EXEL |
Exelixis, Inc.
|
853,093 | $46,416,787 | |
| 5 | APGE |
Apogee Therapeutics, Inc.
|
179,500 | $23,825,035 | |
| 6 | BMRN |
Biomarin Pharmaceutical Inc
|
400,036 | $22,890,059 | |
| 7 | FTRE |
Fortrea Holdings Inc.
|
1,127,337 | $19,615,663 | |
| 8 | ACAD |
Acadia Pharmaceuticals Inc
|
706,664 | $17,878,599 |
All Filings in NAMS
Export CSV
3 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $223,674 | 6,600 | Shares | Defined | 2026-08-14 | |
| 2026-03-31 | $211,266 | 6,600 | Shares | Defined | 2026-05-11 | |
| 2025-12-31 | $231,528 | 6,600 | Shares | Defined | 2026-02-11 | |
| No filing history on record for this holder in this stock. | ||||||